LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・Ardelyx Inc

Ardelyx Inc

Suletud

Sektor Tervishoid

5.6 -2.61

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.57

Max

5.61

Põhinäitajad
By Trading Economics
Sissetulek	-33M -27M
Müük	12M 46M
Aktsiakasum	-0.11
Kasumimarginaal	-57.619
Töötajad	267
EBITDA	-30M -22M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+92.68 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	29. okt 2024

Turustatistika
By TradingEconomics
Turukapital	-7.7M 1.4B
Eelmine avamishind	8.21
Eelmine sulgemishind	5.6

Uudiste sentiment

By Acuity

96%

339 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

5.485 / 6.3 Toetus ja vastupanu

Ardelyx Inc Graafik

Seotud uudised

18. okt 2023, 12:15 UTC

Suurimad hinnamuutused turgudel

Ardelyx Shares Rally Premarket on FDA Approval of Xphozah

Võrdlus sarnastega

Hinnamuutus

Ardelyx Inc Prognoos

Hinnasiht

By TipRanks

92.68% tõus

12 kuu keskmine prognoos

Keskmine 10.79 USD 92.68%

Kõrge 12.5 USD

Madal 7 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Ardelyx Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Ardelyx Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

5.485 / 6.3Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

339 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ardelyx Inc

Ardelyx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines to improve treatment for people with kidney and cardiorenal diseases. The Company's product pipeline includes Tenapanor, IBSRELA, RDX013 Program, and RDX020 Program. The Tenapanor is a medicine for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor for the control of serum phosphorus has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). RDX013 Program is a small molecule potassium secretagogue program for the potential treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis. It has a discovery program targeting the inhibition of intestinal bicarbonate exchange for the treatment of metabolic acidosis.